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Reply to the Editor:
We thank Drs Szentkiralyi, Péterffy, and
Galajda for their thoughtful comments
about suture techniques for tricuspid valve
repair. We believe, as they do, that every
case of moderate tricuspid regurgitation
should be repaired. The options are numer-
ous, but we believe that the suture annulo-
plasty technique we described in this article
will be very successful in these cases. The
implication of their letter is that a suture
annuloplasty likewise would be equal for
very severe cases. We have tended to use a
rigid ring for very severe cases with obvi-
ous clinical manifestation of massive tri-
cuspid insufficiency.
The suture bicuspidization technique de-
scribed can be performed in less then 10
minutes. This technique is effective, reduces
the expense of operations, and certainly
should stimulate the use of a simple repair
techniques in every patient with moderate to
moderately severe tricuspid regurgitation.
Lawrence H. Cohn, MD
Department of Surgery
Brigham and Women’s Hospital
Boston, Mass
doi:10.1016/j.jtcvs.2007.03.011
Intraoperative oral sildenafil
for management of pulmonary
hypertension: A stepping stone
to the future
To the Editor:
I read with great interest the recent article
by Dr Shim and colleagues1 detailing their
experience with oral sildenafil in intraop-
erative pulmonary hypertension (N  53).
Although they controlled for confounders
such as anesthetic depth, hypercarbia, and
serum pH, it is not clear whether they ad-
equately controlled for hyperoxia, a potent
pulmonary vasodilator.2
In their Methods section, they specify
that all patients’ lungs were ventilated with
60% oxygen with standardized mechanical
ventilation, but they fail to report what
range of blood oxygen tensions were ob-
tained and whether they varied signifi-
cantly between study groups. Thus, a major
confounder is not adequately accounted for
in this otherwise interesting paper.
A second limitation with the implemen-
tation of the study findings into one’s prac-
tice is that oral sildenafil is not as conve-
nient in the intraoperative period as is an
inhalational or intravenous formulation.1,2
Because these formulations of sildenafil
exist, this study paves the way for their
investigation in the management of intra-
operative pulmonary hypertension, a
common scenario in patients undergoing
cardiac surgery.
It would be no surprise that these for-
mulations of sildenafil are demonstrated to
be clinically effective pulmonary vasodila-
tors. Of far more clinical importance would
be the clinical trials looking at synergistic
combinations of selective pulmonary vaso-
dilators. There are at least 4 different path-
ways that can be manipulated for synergis-
tic selective pulmonary vasodilation2:
1. Cyclic adenosine monophosphate
pathway with inhaled prostaglandin I2
2. Cyclic guanosine monophosphate
pathway with inhaled nitric oxide
3. Phosphodiesterase 5 inhibition with
sildenafil
4. Endothelin blockade with drugs
such as bosentan
The future is in synergistic approaches to
the management of pulmonary hyperten-
sion, just as we have seen in the manage-
ment of systemic hypertension over the
past 30 years.
I congratulate Dr Shim and colleagues
on a thought-provoking study. I look for-
ward to their feedback about these intraop-
erative considerations.
John G. T. Augoustides MD, FASE
Assistant Professor
Department of Anesthesiology and Critical Care
Hospital of the University of Pennsylvania
Philadelphia, Pa
Financial support: Department of Anesthesiol-
ogy and Critical Care, Hospital of the Univer-
sity of Pennsylvania.
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Reply to the Editor:
We appreciate the constructive comments
by Dr Augoustides regarding our study.1
He raised the issue of whether hyperoxia,
which is a potent pulmonary vasodilator,
was adequately controlled between the
control and sildenafil groups in our study.
The arterial oxygen tension (PaO2) levels
were 271  89 mm Hg versus 254  108
mm Hg (P  .602) before the first hemo-
dynamic measurement and 276  48 mm
Hg versus 235  55 mm Hg (P  .03)
immediately after the last measurement
with 60% oxygen in the control and silde-
nafil groups, respectively. There were no
significant changes in the PaO2 values
within each group.
Hypoxic pulmonary vasoconstriction
has been well studied for decades, with the
stimulus identified as both mixed venous
and alveolar oxygen tension in small arter-
ies and systemic PaO2 in large pulmonary
vessels.2 However, no comprehensive data
exist regarding graded response of the pul-
monary vasculature to changes in PaO2
above 120 mm Hg (hyperoxia), especially
in patients with long-standing valvular
heart disease with concomitant pulmonary
hypertension, as in our study. In an animal
study, Rudolph and Yuan3 studied the re-
lationship between PaO2 and pulmonary
vascular resistance and demonstrated that
there is no further decrease in pulmonary
vascular resistance above the PaO2 of 50 to
60 mm Hg. Therefore, although the PaO2
was lower in the sildenafil group after the
last measurement, this should not have any
further clinically significant effects on the
pulmonary vascular resistance.
We agree with Augoustides that proper
control of PaO2 between the groups should
be mentioned to clarify any confounding
factors.
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We also agree that further studies with
an intravenous form of sildenafil, which is
currently not available in our country,
should be performed, especially with re-
gard to the period of weaning from cardio-
pulmonary bypass, and we hope that our
study will draw much attention and further
clinical research in this area.
Jae Kwang Shim, MD
Yong Seon Choi, MD
Young Lan Kwak, MD
Department of Anesthesiology and Pain Medicine
Anesthesia and Pain Research
Seoul, South Korea
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Redo mitral valve repair
To the Editor:
We read with interest the recent article of
Suri and colleagues1 in the Journal. The
authors reported their 35-year experience
of redo surgery for mitral valve (MV) re-
pair failure in degenerative disease. They
concluded that MV re-repair should be per-
formed whenever technically feasible ow-
ing to the improved survival and better left
ventricular performance allowed by the
procedure in comparison to MV replace-
ment. Although our surgical management
of such patients is similar, we found some
concerns with their reported data that need
clarification.
Most patients were operated on between
1980 and 2000. Regarding the survival
curve (Figure 1 from their article), only
25% of patients from both groups (repair
and replacement) were still at risk at 5
years. Because mortality within that time
frame was certainly not 75%, that means
that many patients were lost to follow-up.
This raises questions about the accuracy of
the survival comparisons between the two
groups. On the other hand, it would have
been interesting to have the actuarial sur-
vivals at 10, 15, and 20 years inasmuch as
the study extends over a period of 35 years.
There is some inconsistency with the
results of multivariate analysis of the pre-
dictors of late survival. According to the
authors, “late” survival was better after MV
re-repair. Survival was also better when the
indication for reoperation was recurrent
mitral regurgitation. However, this later
group of patients (with regurgitation) un-
derwent predominantly MV replacement.
Do the authors have an explanation for
these contradictory results?
It would have been interesting to have
some echocardiographic data regarding the
MV function when reading the results of a
(long-term) MV repair study.
Six patients from the re-repair group
underwent a third operation during their
follow-up. Unfortunately, the intraopera-
tive anatomic findings were not reported.
In our experience, failure of re-repair is
usually related to retraction of the posterior
leaflet (type IIIa). This lesion is easily cor-
rected by pericardial patch extension of the
posterior leaflet, even in a third operation.2
Most important, we believe that surgeons
should carefully inspect the posterior leaf-
let for any retraction before performing re-
repair for primary MV repair failure. Even
when failure is due to an anterior leaflet
prolapse, surgeons should not hesitate to
extend the posterior leaflet when it appears
retracted, even moderately. We believe that
is a simple way to improve the long-term
results of MV re-repair.
Finally, our surgical experience in MV
repair failure in degenerative disease is in
favor of re-repair. We therefore agree with
the conclusion from the Mayo Clinic study,
but we do have some concerns regarding
the way it was presented.
Rachid Zegdi, MD, PhD
Paul Achouh, MD
Jean-Noël Fabiani, MD
Université René Descartes—Paris V
Department of Cardiovascular Surgery
Hôpital Européen Georges Pompidou
Paris, France
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Reply to the Editor:
We thank Drs Zegdi, Achouh, and Fabiani
for their comments and are happy to pro-
vide the requested clarifications.
Regarding the issue of patients at risk in
the survival analysis, mean follow-up was
3.3 years, and 73% of patients alive at
follow-up had this information available
within 5 years of the date of review. Ques-
tionnaires were sent to all patients; how-
ever, current US Health Insurance Portabil-
ity and Accountability Act (HIPAA) laws
prohibit telephone inquiries to those who
do not respond to mailed surveys. We also
tracked vital statistics through the Social
Security Death Index and have no reason to
suspect that we missed a high number of
deaths. We believe that the remaining pa-
tients were lost to follow-up at random.
Of 145 patients undergoing reoperation
for recurrent mitral regurgitation alone, 64
(44%) had re-repair and 81 (56%) had re-
placement. The concern in the letter to the
Editor as to whether recurrent mitral regur-
gitation and mitral re-repair are “contradic-
tory” predictors of improved long-term sur-
vival is somewhat perplexing. Multivariate
analyses attempt to control for confounding
interrelated variables and identify indepen-
dent predictors of end points such as sur-
vival, which is impossible to accomplish
from a simple comparison of univariately
significant factors alone.
The echocardiographic follow-up of
these patients is an area of ongoing inves-
tigation by our group and is currently being
analyzed in other clinical studies. In our
practice, the recurrence of moderate-to-se-
vere mitral regurgitation or significant ste-
nosis usually leads to surgical assessment
and intervention.
All patients in our study had primary
mitral regurgitation owing to purely degen-
erative mitral valve disease. Leaflet retrac-
tion is usually rare unless ischemic or inflam-
matory components coexist. Additionally, we
do not generally perform quadrangular resec-
tions and sliding repairs, which may explain
the frequency with which Dr Zegdi’s group
reports mitral leaflet retraction at reoperation.
The 6 patients who required a second re-
Letters to the Editor
268 The Journal of Thoracic and Cardiovascular Surgery ● July 2007
